Rational Design of CRISPR/Cas9-engineered TIL Therapies

Time: 12:00 pm
day: Day Two

Details:

• Harnessing CRISPR to identify TIL-enhancing targets

• Analyzing designing and manufacturing next-gen TIL therapies with increased anti-tumor potency

• Examining KSQ-001 and KSQ-004 as single- and dual-edited CRISPR/Cas9- engineered TIL products

Speakers: